A Study of LY3819469 in Participants With Impaired and Normal Renal Function

Inclusion Criteria: Have a body mass index within the range 19.0 to 42.0 kilograms per meter squared (kg/m²) Men who agree to use highly effective or effective methods of contraception and women not of childbearing potential (WNOCBP) may participate in this trial Participants with Normal Renal Function: Have estimated glomerular filtration rate (eGFR) determined by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) greater than or equal to 90 milliliter per minute (mL/min) Participants with Renal Impairment: Severe renal impairment: Have eGFR determined by CKD-EPI of less than 30 mL/min and not requiring dialysis ESRD: Participants who have been on a stable hemodialysis schedule for at least 3 months prior to planned dosing Exclusion Criteria: Have a history or presence of an underlying disease, or surgical, physical, medical, or psychiatric condition Have any abnormality in the 12-lead electrocardiogram (ECG) Hemoglobin less than 8 grams per deciliter (g/dL) and clinically significant anemia symptoms Have known allergies to LY3819469, related compounds or any components of the formulation, or a history of significant atopy Have participated in any Lp(a) siRNA therapeutic clinical trial within the last 1 year